An SEO plan sized for the team that actually has to run it.
Mid-size pharma SEO is scoped against real internal publishing capacity — a two- or three-person marketing function across several markets — rather than against what a much larger content team could theoretically produce.
The regulatory and content complexity matches a large company, but the internal team producing it usually does not — the SEO plan has to be scoped against real publishing capacity, not portfolio size.
A team of two or three people is often responsible for corporate, product and HCP content at once, which most agencies scope as if it were a large enterprise account. Swapping the company name into a generic pharmaceutical SEO checklist never actually accounts for that.
A content calendar scoped to what your actual team can sustain, research prioritised by real impact rather than volume, and an audit of what is currently costing more reviewer time than it earns in visibility.
The content calendar and technical scope are built against what a two- or three-person marketing function can actually sustain across several markets, not against what a large pharma content team could produce.
Mid-size pharmaceutical companies typically carry more products, across more markets, than the marketing team can properly support. Spreading search work evenly across that portfolio guarantees that nothing reaches the depth required to rank, which is how these programmes come to look ineffective. Concentrating on the two or three products where search demand, commercial priority and available approved content actually overlap produces visible movement within a plausible timeframe. The remaining portfolio is better served by an accurate, well-structured baseline page than by a half-finished attempt at depth that consumes the same review capacity.
Operating across several countries with one website introduces problems that no amount of good content will solve on its own: language and regional targeting, duplicate pages across market variants, differing product information for the same molecule, and healthcare professional gating that varies by jurisdiction. These are configuration decisions, and getting them wrong quietly caps every market’s visibility regardless of content quality. Resolving them once is usually the highest-return work available to a mid-size company, because it lifts the entire existing portfolio rather than one product at a time.
What comes up when planning search visibility for this category.
Variants of “pharma website redesign” or “multi-market pharma content platform”, almost never the broad category term an untargeted keyword plan starts from instead. This search usually comes from someone on a small marketing team already frustrated with an existing site, often triggered by a market expansion or a rebrand, rather than from someone browsing agency directories looking for a first vendor to evaluate.
A two- or three-person marketing team searches for practical fixes — website redesign, market expansion, content workflow — rather than agency credentials, because they are already stretched across corporate, product and HCP content. The technical constraint is capacity: the site and its SEO plan need to support several markets without requiring the team to manage a separate build for each one added later.
Yes — see Mid-Size Pharma for the full range of platforms and content we build for this sector, including the multi-market content structure and workflow tooling that lets a small team manage corporate, product and HCP content without adding headcount for each new language or region. Most mid-size pharma clients start with one market and expand the same platform outward as capacity allows.
That is a common, sensible starting point — the platform is built to expand market by market later without a rebuild, so starting narrow does not create technical debt. We structure content types, language handling and workflow permissions from the first market onward, so adding a second or third market later means configuring new content rather than re-architecting the site to support something it was never designed for.
With the technical configuration across markets, then with two or three products rather than the whole portfolio. Market targeting and duplicate content problems suppress everything at once, so fixing them raises the baseline for products you are not otherwise working on. After that, depth on a small number of priorities beats thin coverage everywhere — and it gives you a demonstrable result to justify further resource, which spreading the effort thinly almost never does.
Traffic that never seems to convert into the searches that actually matter for this category. Tell us what you have published and we will tell you what is missing. Tell us how "laboratory website redesign" performs for you today and we will tell you why.